Marbofloxacin hydrochloride

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H19FN4O4.ClH
Molecular Weight	398.817
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of Marbofloxacin hydrochloride

SMILES

Cl.CN1CCN(CC1)C2=C3OCN(C)N4C=C(C(O)=O)C(=O)C(C=C2F)=C34

InChI

InChIKey=OCRYFLKYXNBUEY-UHFFFAOYSA-N

InChI=1S/C17H19FN4O4.ClH/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25;/h7-8H,3-6,9H2,1-2H3,(H,24,25);1H

HIDE SMILES / InChI

Description

Marbofloxacin is an anti-bacterial veterinary medication which is approved by FDA and EMEA for the treatment of bacterial diseases in dogs and cats. The drug exerts its action by inhibiting bacterial DNA gyrase.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial DNA gyrase 66	Inhibitor 8,297

Conditions

Condition	Modality	Highest Phase	Product
Skin infections 59	Curative	Approved 8,429	Zeniquin
Soft tissue infections 4	Curative	Approved 8,429	Zeniquin
Urinary tract infections (cystitis) 3	Curative	Approved 8,429	Zeniquin

PubMed

Show entries

Title	Date	PubMed
Pharmacokinetics of marbofloxacin after intravenous and intramuscular administration to ostriches.	2005 Nov	16266851
A comparative study of two antimicrobial/anti-inflammatory formulations in the treatment of canine otitis externa.	2005 Oct	16238809
Pharmacokinetics of marbofloxacin after single intravenous and repeat oral administration to cats.	2005 Sep	16129342
[Resistance of mastitis pathogens in northern Germany].	2005 Sep-Oct	16206927
Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves.	2006 Dec	17106223

Showing 1 to 5 of 50 entries

Previous1 2 3 4 5…10Next

Patents

Sample Use Guides

In Vivo Use Guide

1.25 mg per pound (/lb) of body weight once daily, but may be increased to 2.5 mg/lb of body weight once daily.

Route of Administration: Other

In Vitro Use Guide

MIC50 values of marbofloxacin against pathogens isolated from skin, soft tissue and urinary tract infections in dogs were: Staphylococcus intermedius - 0.25 ug/ml, Escherichia coli - 0.03 ug/ml, Proteus mirabilis - 0.06 ug/ml, Beta-hemolytic Streptococcus, (not Group A or Group B) - 1 ug/ml, Streptococcus, Group D enterococcus - 1 ug/ml, Pasteurella multocida - 0.015 ug/ml, Staphylococcus aureus - 0.25 ug/ml, Enterococcus faecalis - 2 ug/ml, Klebsiella pneumoniae - 0.06 ug/ml.

Show entries

Name

Type

Language

Marbofloxacin hydrochloride

Common Name

English

9-Fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic acid hydrochloride

Systematic Name

English

7H-Pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, monohydrochloride

Systematic Name

English

7H-Pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, hydrochloride (1:1)

Systematic Name

English

7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid;hydrochloride

Systematic Name

English

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Code System

Code

Type

Description

CAS

115551-26-3

PRIMARY